Why is Veracyte stock sinking Thursday?
<?xml encoding="utf-8" ?> Veracyte Inc. VCYT stock traded lower Thursday after the company reported weaker-than-expected ...
Model output · Signal date 2026-11-06
Veracyte, Inc. (VCYT) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
Unlock rating and forecasts
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
of 5150 stocks scored
Rank correlation · 90D
-15.0%
Spearman, 357 dates
Market Cap
$1.94B
small-cap · #12 of 27 peers
Summary
Veracyte, Inc. (VCYT) stock forecast summary
Our AI scores Veracyte, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Veracyte, Inc. is a small-cap company with a market capitalization of $1.94B. It ranks number 12 by market capitalization among the 27 Services-Medical Laboratories issuers in our coverage with a current forecast.
For VCYT, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -15.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 12.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, VCYT included.
Price
VCYT price chart and AI forecast
Cross-section · 2026-11-06
How VCYT ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-09-30
Veracyte, Inc. (VCYT) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Medical Laboratories peers listed below that report each metric.
Valuation & Market
| Metric | VCYT | Rank |
|---|---|---|
| Market Cap | $1.94B | 12/27 |
| P/E Ratio | 25.17x | 5/6 |
| P/B Ratio | 1.36x | 16/21 |
| EPS | $0.96 | – |
| Book Value/Share | $17.83 | – |
| Revenue/Share | $7.24 | – |
| FCF/Share | $2.01 | – |
Profitability & Margins
| Metric | VCYT | Rank |
|---|---|---|
| ROIC | 6.7% | 6/22 |
| Gross Margin | 72.0% | 2/15 |
| Operating Margin | 17.1% | 3/21 |
| EBT Margin | 20.3% | 3/21 |
| Tax Rate | -7.3% | – |
Financial Health
| Metric | VCYT | Rank |
|---|---|---|
| Current Ratio | 5.56x | 7/24 |
| Quick Ratio | 5.25x | 5/11 |
| D/E Ratio | 0.10x | 18/21 |
| Financial Leverage | 1.10x | 18/21 |
| Working Capital | $384M | 9/24 |
Cash Flow
| Metric | VCYT | Rank |
|---|---|---|
| Operating Cash Flow | $174M | 6/25 |
| Free Cash Flow | $162M | 4/17 |
| Capital Spending | -$12M | 8/17 |
| OCF Growth YoY | 60.6% | 4/9 |
| FCF Growth YoY | 64.9% | 1/5 |
| FCF/Sales | 27.8% | 2/16 |
| CapEx/Sales | 2.0% | 13/16 |
Operational Efficiency
| Metric | VCYT | Rank |
|---|---|---|
| Asset Turnover | 0.37x | 12/18 |
| Receivables Turnover | 10.2x | 4/19 |
| Fixed Assets Turnover | 23.4x | 1/17 |
| Days Sales Outstanding | 36 days | 16/19 |
Income Statement
| Metric | VCYT | Rank |
|---|---|---|
| Total Revenue | $582M | 7/19 |
| Operating Income | $99M | 4/24 |
| R&D Expense | $110M | 6/18 |
| SG&A Expense | $325M | 9/19 |
Dividend & Shareholder Information
| Metric | VCYT | Rank |
|---|---|---|
| Shares Outstanding | 80M | – |
| EPS Growth | 166.7% | 1/6 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $468M | 29.7% of assets |
| Cash & Short-term Investments | $200M | 12.7% of assets |
| Accounts Receivable | $57M | 3.6% of assets |
| Inventory | $26M | 1.6% of assets |
| Total Liabilities | $140M | 8.9% of assets |
| Short-term Debt | $74M | 4.7% of assets |
Quarterly Financial Reports
VCYT quarterly financials and insider trading
Industry Peers · Services-Medical Laboratories
Veracyte, Inc. (VCYT) industry peers
Companies classified under the same SEC industry code as Veracyte, Inc. (Services-Medical Laboratories): 28 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| VCYT Veracyte, Inc. | $1.94B | |
| NTRA Natera, Inc. | $44.78B | |
| LH Labcorp Holdings Inc. | $29.77B | |
| DGX Quest Diagnostics Inc | $28.12B | |
| GH Guardant Health, Inc. | $20.25B | |
| CAI Caris Life Sciences, Inc. | $7.13B | |
| RDNT Radnet, Inc. | $5.98B | |
| GRAL Grail, Inc. | $5.42B | |
| BLLN Billiontoone, Inc. | $5.38B | |
| CDNA Caredx, Inc. | $4.13B | |
| CELC Celcuity Inc. | $3.27B | |
| FTRE Fortrea Holdings Inc. | $2.12B | |
| PSNL Personalis, Inc. | $1.69B | |
| LMRI Lumexa Imaging Holdings, Inc. | $1.27B | |
| FRNM Freenome, Inc. | $1.12B | |
| CSTL Castle Biosciences Inc | $993M | |
| FLGT Fulgent Genetics, Inc. | $513M | |
| XGN Exagen Inc. | $184M | |
| BNR Burning Rock Biotech Ltd | $143M | |
| BDSX Biodesix Inc | $90M | |
| SERA Sera Prognostics, Inc. | $82M | |
| MDXH Mdxhealth Sa | $14M | |
| AMS American Shared Hospital Services | $8M | |
| ACON Aclarion, Inc. | $4M | |
| ADVB Advanced Biomed Inc. | $3M | |
| BGLC Bionexus Gene Lab Corp | $3M | |
| FCHS First Choice Healthcare Solutions, Inc. | $150K | |
| RNLXY Renalytix Plc | N/A |
Where VCYT sits on the market map
Industrial Applications and Services · Services-Medical Laboratories
News
Veracyte, Inc. (VCYT) stock news
Transcript : Veracyte, Inc., Q3 2026 Earnings Call, Nov 05, 2026
Veracyte, Inc. authorizes a Buyback Plan. CI Nov. 04 Veracyte, Inc. announces an Equity Buyback for $100 million worth of its shares. CI Nov. 04 Earnings Flash (VCYT) Veracyte, Inc. Posts Q3 Adjusted ...
Veracyte Q3 Earnings Call Highlights Slower Growth and Added Investment
VCYT beats Q3 earnings estimates but trims its 2026 revenue outlook as Decipher growth slows and investments in breast and bladder cancer testing rise.
FAQ
Veracyte, Inc. (VCYT) stock forecast FAQ
What is the Veracyte, Inc. (VCYT) stock forecast?
Our AI scores Veracyte, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Veracyte, Inc. stock predictions?
For VCYT, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -15.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 12.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Veracyte, Inc. forecasts updated?
Veracyte, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Veracyte, Inc.'s industry peers?
28 issuers in our coverage, VCYT included, share the SEC industry code Services-Medical Laboratories. The largest are: Natera, Inc. (NTRA), Labcorp Holdings Inc. (LH), Quest Diagnostics Inc (DGX), Guardant Health, Inc. (GH), Caris Life Sciences, Inc. (CAI), Radnet, Inc. (RDNT).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.